EndoGastric Solutions TM Announces Results Of EsophyX TM Multi-Center GERD Study
EndoGastric Solutions, the world leader in natural orifice surgery products and procedures, announces outstanding results at the completion of 1-year follow-up on GERD patients in the phase 2 multi-center study of the first generation transoral incisionless fundoplication (TIF 1) procedure and first-generation EsophyX device.
New Advice On Treating GERD: Johns Hopkins Health Alerts Reports On The Latest Research
Johns Hopkins Health Alerts has just published a review of the new GERD guidelines, for safe, effective treatment of your acid reflux. Treating GERD EffectivelyThere are four types of treatments for gastroesophageal reflux disease (GERD): lifestyle measures, medication, surgery, and endoscopic procedures. Why it is important to treat GERDTreating GERD is important.
FDA Approves Nexium For Use In Children Ages 1-11 Years
The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD). The agency approved Nexium in two forms, a delayed-release capsule and liquid form. Nexium is approved in 10 milligrams (mg) or 20 mg daily for children 1-11 years old compared to 20 mg or 40 mg recommended for pediatric patients 12 to 17 years of age.
Orexo Announces Results Confirming The Clinical Profile Of OX17 In Reflux Disease GERD
New clinical data from a phase II study confirms the competitive profile of Orexo's product OX17 in GERD patients, i.e. fast, effective and sustained inhibition of gastric acid production, a prerequisite for effective symptom relief in the patient. The result demonstrates the clinical potential of OX17 and is an important step in the development of a competitive product. GERD, gastroesofageal reflux disease, is a common ailment in the Western world.
Santarus Announces Development Program For New ZEGERID Prescription Product
Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, announced that it is developing a new tablet formulation to add to its ZEGERID family of branded prescription pharmaceutical products. The new formulation is a swallowable tablet that combines immediate-release omeprazole, a proton pump inhibitor (PPI), with a mix of buffers. Santarus plans to undertake clinical and stability studies with the tablet in preparation for the submission of a New Drug Application to the U.S.
FDA Approves VYVANSE TM lisdexamfetamine Dimesylate , The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults
Shire plc (LSE: SHP) (NASDAQ: SHPGY, ), the global specialty biopharmaceutical company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE(TM) (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
AAP And American Heart Association Clarify Statement On ADHD And Electrocardiograms
The American Heart Association released on April 21, 2008, a statement about cardiovascular evaluation and monitoring of children receiving drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a result of language in the news release and the statement as published, there have been conflicting interpretations of the recommendations regarding the use of an electrocardiogram (ECG) in assessing children with ADHD who may need treatment with medications.
Recurring Symptoms Experienced By Nearly 40 Percent Of GERD Patients Taking PPIs
Despite daily use of doctor-recommended proton pump inhibitors (PPIs) to control gastroesophageal reflux disease (GERD) symptoms, nearly 40 percent of patients who take them continue to experience breakthrough, which is a return of GERD symptoms, such as acid regurgitation and heartburn.
Medication Improves Driving Ability ADHD Patients
The use of the medication methylphenidate considerably improves the driving ability of people with ADHD. This was shown in research done by Joris Verster of Utrecht University, The Netherlands. The study will appear in the May 2008 issue of Journal of Psychopharmacology.People with ADHD are often prescribed methylphenidate (brand name Ritalin) to counteract hyperactive behavior and attention dysfunction that may negatively affect their driving ability.
Heart Tests Should Be Carried Out Before Treatment With Stimulant Drugs For Children With ADHD
Children with attention deficit hyperactivity disorder (ADHD) should get careful cardiac evaluation and monitoring - including an electrocardiogram (ECG) - before treatment with stimulant drugs, a new American Heart Association statement recommends.The scientific statement on Cardiovascular Monitoring of Children and Adolescents with Heart Disease Receiving Stimulant Drugs is published online in Circulation: Journal of the American Heart Association.